A New Gold Standard? How One Injection Is Redefining Equine Lameness Care

AUSTIN, TX – August 06, 2026 – For the multi-billion dollar performance horse industry, lameness is a persistent and costly adversary. It can sideline a prized athlete, derail a competitive season, and lead owners and veterinarians down a frustrating path of treatments with mixed results. Now, a rigorous new clinical trial suggests a significant paradigm shift may be on the horizon, centered on a single, ready-to-use injection that is outperforming the established standards of care.

The breakthrough comes from Equine Performance Labs (EPL), which recently announced the publication of a multi-center study on its umbilical cord allograft, equicenta® CTM. Published in the peer-reviewed journal Frontiers in Veterinary Science, the trial demonstrates that the therapy not only improves clinical signs of lameness more effectively than conventional treatments but also nearly triples the odds of a horse returning to its previous level of performance. For an industry built on marginal gains, this represents a monumental leap forward.

The Science of Superiority

What sets this announcement apart in a field buzzing with regenerative therapies is the sheer rigor of the study's design. Led by the highly respected Dr. Alicia L. Bertone of The Ohio State University, the pragmatic, prospective controlled trial enrolled 138 lame performance horses across eight different veterinary practices in the U.S.

Crucially, the study did not compare equicenta® CTM against a placebo. Instead, it pitted the novel therapy head-to-head against clinician-selected "standard of care" (SOC) treatments, which included the very biologics—like hemoderivatives—that are currently popular choices in equine medicine. This real-world design provides a far more practical measure of a product's value in a clinical setting.

The results were decisive. Across every measured outcome, equicenta® CTM demonstrated superiority:
* Rapid Recovery: Horses treated with the allograft showed greater improvement in pain and swelling within two weeks, and in lameness by four weeks.
* Sustained Results: The clinical superiority was not fleeting; it was sustained through the 12-week mark.
* Return to Work: The odds of a horse returning to its prior performance level were 2.72-to-1 in favor of the equicenta® CTM group.
* Objective Proof: The findings weren't just based on observation. Objective kinematic gait analysis—a high-tech method of measuring movement—confirmed a significantly greater improvement in lameness.
* Enhanced Safety: The therapy was also associated with fewer injection-related adverse events compared to the standard treatments.

"This is what we set out to build: a science-first therapy that gives veterinarians and horse owners something they can trust and use with confidence,” said Heather Rogers, CEO of Equine Performance Labs, in a statement. Her emphasis on trust speaks directly to a long-standing challenge in the regenerative medicine space.

A New Benchmark in a Crowded Field

The market for equine lameness treatments is a complex landscape. It ranges from traditional anti-inflammatories and corticosteroid injections, which manage symptoms but may not promote deep healing, to a growing array of regenerative options. Therapies like Platelet-Rich Plasma (PRP) and autologous stem cells (derived from the horse's own body) have offered hope but come with their own logistical hurdles. They often require patient-side harvesting and processing, introducing variability and adding time and cost to the procedure.

This is where equicenta® CTM introduces a powerful business implication: radical convenience. As a cryopreserved, "off-the-shelf" allogeneic product, it eliminates the entire chain of harvesting, culturing, and processing. A veterinarian can simply thaw and inject, armed with the knowledge that the product's consistency is backed by a robust, multi-center trial.

This innovation arrives at a critical time. The U.S. equine regenerative medicine market, valued at over $50 million in 2024, is projected to exceed $80 million by 2030. As owners invest more in the health and longevity of their equine partners, the demand for effective, reliable, and efficient solutions is intensifying. By providing a product that is not only clinically superior but also logistically simpler, Equine Performance Labs is positioning itself to capture a significant share of this growing market.

The Business of Better Medicine

The practical benefits of this new therapy extend from the clinic to the stable. For veterinarians, the ability to pull a validated, ready-to-use treatment from the freezer streamlines workflow and allows them to treat more horses with greater confidence. It transforms a potentially multi-step, variable procedure into a predictable and efficient one.

For horse owners, the value proposition is even more direct. A nearly threefold increase in the likelihood of returning a valuable performance horse to its job is a powerful economic driver. It means less time spent on costly rehabilitation, fewer lost entry fees, and a quicker return on investment for an animal that is both a partner and a significant asset. Furthermore, improved owner-reported outcomes for hair coat, body condition, and overall quality of life suggest benefits that transcend simple performance metrics. While specific pricing is not public, the potential savings in time and secondary treatments, coupled with the high success rate, could make it a highly cost-effective option. This is especially true if, as expected, it becomes covered by major equine insurance providers who already reimburse for other regenerative therapies.

Navigating the Path to Market

Bringing any new animal biologic to market involves navigating the regulatory framework of the FDA's Center for Veterinary Medicine (CVM), which oversees such products to ensure their safety and effectiveness. While many therapies in this space operate under evolving guidelines, EPL's strategy appears to be one of leading with overwhelming data.

In an industry where some experts privately note that the evidence behind certain regenerative treatments can be "slim" or based on small-scale studies, EPL's investment in a large, prospective, and controlled trial is a significant differentiator. It preempts questions of efficacy by providing clear, peer-reviewed proof. This "science-first" approach, as CEO Heather Rogers calls it, is not just about good medicine; it's a shrewd business strategy designed to build a brand founded on credibility.

By delivering a single, ready-to-use injectable that helps more horses get back to doing what they love, backed by one of the most rigorous trials in equine medicine to date, Equine Performance Labs is not just launching a product. It is setting a new and formidable benchmark for what veterinarians and horse owners should expect from regenerative therapy.